Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zai Lab Ltd ( (HK:9688) ) has shared an update.
Zai Lab Limited reported a 49% increase in net product revenue for 2024, reaching $397.6 million, driven by the successful launch and sales of VYVGART, as well as increased sales of ZEJULA and NUZYRA. The company also saw a 23% reduction in net loss to $257.1 million, attributed to revenue growth outpacing operating expenses, despite challenges such as decreased interest income and increased foreign currency loss.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative therapies. The company is primarily engaged in the healthcare industry, with a market focus on oncology, autoimmune, and infectious diseases.
YTD Price Performance: 31.15%
Average Trading Volume: 400
Technical Sentiment Signal: Sell
Current Market Cap: €3.55B
Learn more about 9688 stock on TipRanks’ Stock Analysis page.